NuvOx Therapeutics
PrivateLast Round
Grant
Sep 26, 2025
Total Funding Raised
$20.69M
Company Overview
NuvOx Therapeutics operates in Healthcare & Life Sciences and is based in Tucson, Arizona. Its latest recorded funding round was a Grant round in September 2025.
NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing a first-in-class oxygen therapeutic designed to reverse tissue hypoxia in life-threatening diseases such as cancer, stroke, and respiratory distress.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NuvOx Therapeutics Comparables
Compare NuvOx Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prolong Pharmaceuticals, LLC | 88% | |
| Omniox, Inc. | 83% | |
| Aurum Biosciences Ltd | 81% |
For institutional investors. Book with your work email.
NuvOx Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 26, 2025 | ||||
| Convertible Debt | Sep 18, 2023 | ||||
| Grant | Feb 11, 2022 | ||||
| Grant | Apr 12, 2017 | ||||
| Grant | Oct 17, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NuvOx Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Gulf South Angels | Convertible Debt |
| VisionTech Partners | Convertible Debt |
| U.S. Department of War | Grant |
| MEDA Angels | Convertible Debt |
| National Heart, Lung, and Blood Institute | Grant |
| New World Angels | Convertible Debt |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 26, 2025
$2M grant from the National Cancer Institute
- Jul 23, 2025
Grew 30% QoQ, from 10 to 13 employees.
For institutional investors. Book with your work email.
NuvOx Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NuvOx Therapeutics's valuation, stock price, and market status.
Is NuvOx Therapeutics a public or private company?
NuvOx Therapeutics is a private company.
What is the current stock price of NuvOx Therapeutics?
NuvOx Therapeutics is a private company, so its shares have no public market price. Caplight tracks NuvOx Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NuvOx Therapeutics worth (valuation)?
Valuation information for NuvOx Therapeutics is not publicly available.
Can I buy NuvOx Therapeutics stock?
NuvOx Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NuvOx Therapeutics's last funding round?
NuvOx Therapeutics's most recent funding round was Grant on September 26, 2025.
Who are the main investors in NuvOx Therapeutics?
Key investors in NuvOx Therapeutics include National Cancer Institute, U.S. Department of War, National Heart, Lung, and Blood Institute, New World Angels.
Will NuvOx Therapeutics IPO soon?
No public IPO plans have been announced for NuvOx Therapeutics.
How can I track NuvOx Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NuvOx Therapeutics's shares on secondary markets.